NYQ·Healthcare·$3.5B·#211 / 520 in Healthcare
OGN Organon & Co.
51SPECULATIVE
CATEGORY BREAKDOWN
GROWTH0
QUALITY63
STABILITY67
VALUATION100
GOVERNANCE32
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-2.9%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
53.3%
75
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
1149.5%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
0.6x
100
< 3x strong
Rule of 40
Growth rate plus operating margin
17
45
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
0.4%
3
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+1.8%
89
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE OGN WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when OGN's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.